156 related articles for article (PubMed ID: 25400334)
1. Mediators of mast cells in bullous pemphigoid and dermatitis herpetiformis.
Zebrowska A; Wagrowska-Danilewicz M; Danilewicz M; Stasikowska-Kanicka O; Kulczycka-Siennicka L; Wozniacka A; Waszczykowska E
Mediators Inflamm; 2014; 2014():936545. PubMed ID: 25400334
[TBL] [Abstract][Full Text] [Related]
2. Tissue Factor in Dermatitis Herpetiformis and Bullous Pemphigoid: Link between Immune and Coagulation System in Subepidermal Autoimmune Bullous Diseases.
Zebrowska A; Wagrowska-Danilewicz M; Danilewicz M; Wieczfinska J; Pniewska E; Zebrowski M; Waszczykowska E; Wozniacka A; Eusebio M; Pietruczuk M; Pawliczak R
Mediators Inflamm; 2015; 2015():870428. PubMed ID: 27057091
[TBL] [Abstract][Full Text] [Related]
3. IL-17 expression in dermatitis herpetiformis and bullous pemphigoid.
Zebrowska A; Wagrowska-Danilewicz M; Danilewicz M; Stasikowska-Kanicka O; Cynkier A; Sysa-Jedrzejowska A; Waszczykowska E
Mediators Inflamm; 2013; 2013():967987. PubMed ID: 23970818
[TBL] [Abstract][Full Text] [Related]
4. Autoimmunity-driven enzymatic remodeling of the dermal-epidermal junction in bullous pemphigoid and dermatitis herpetiformis.
Gornowicz-Porowska J; Bowszyc-Dmochowska M; Dmochowski M
Autoimmunity; 2012 Feb; 45(1):71-80. PubMed ID: 21916544
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T cells as well as IL-10 are reduced in the skin of patients with dermatitis herpetiformis.
Antiga E; Quaglino P; Pierini I; Volpi W; Lami G; Bianchi B; Del Bianco E; Renzi D; Baroni G; Novelli M; Ponti R; Papini M; Di Lollo S; Calabrò AS; Fabbri P; Caproni M
J Dermatol Sci; 2015 Jan; 77(1):54-62. PubMed ID: 25465638
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid.
Niimi Y; Pawankar R; Kawana S
Int Arch Allergy Immunol; 2006; 139(2):104-13. PubMed ID: 16374020
[TBL] [Abstract][Full Text] [Related]
7. The role of apoptosis in the pathogenesis of dermatitis herpetiformis.
Caproni M; Torchia D; Antiga E; Degl'Innocenti D; Barletta E; Baroni G; Santucci M; Fabbri P
Int J Immunopathol Pharmacol; 2005; 18(4):691-9. PubMed ID: 16388717
[TBL] [Abstract][Full Text] [Related]
8. Expression of the JAK/STAT Signaling Pathway in Bullous Pemphigoid and Dermatitis Herpetiformis.
Juczynska K; Wozniacka A; Waszczykowska E; Danilewicz M; Wagrowska-Danilewicz M; Wieczfinska J; Pawliczak R; Zebrowska A
Mediators Inflamm; 2017; 2017():6716419. PubMed ID: 29203970
[TBL] [Abstract][Full Text] [Related]
9. Demonstration of collagenase and elastase activities in the blister fluids from bullous skin diseases. Comparison between dermatitis herpetiformis and bullous pemphigoid.
Oikarinen AI; Zone JJ; Ahmed AR; Kiistala U; Uitto J
J Invest Dermatol; 1983 Sep; 81(3):261-6. PubMed ID: 6309988
[TBL] [Abstract][Full Text] [Related]
10. Serum levels and tissue expression of interleukin-31 in dermatitis herpetiformis and bullous pemphigoid.
Bonciani D; Quintarelli L; Del Bianco E; Bianchi B; Caproni M
J Dermatol Sci; 2017 Aug; 87(2):210-212. PubMed ID: 28465041
[No Abstract] [Full Text] [Related]
11. Serum eosinophil cationic protein, myeloperoxidase, tryptase, eotaxin and Th2-L-like cytokines in Dermatitis herpetiformis.
Caproni M; Cardinali C; D'Agata A; Selvaggi W; Fabbri P
Int Arch Allergy Immunol; 2002 May; 128(1):67-72. PubMed ID: 12037403
[TBL] [Abstract][Full Text] [Related]
12. Correlation between IL36α and IL17 and Activity of the Disease in Selected Autoimmune Blistering Diseases.
Żebrowska A; Woźniacka A; Juczyńska K; Ociepa K; Waszczykowska E; Szymczak I; Pawliczak R
Mediators Inflamm; 2017; 2017():8980534. PubMed ID: 28611508
[TBL] [Abstract][Full Text] [Related]
13. Dermatitis herpetiformis and bullous pemphigoid: a developing association confirmed by immunoelectronmicroscopy.
Setterfield J; Bhogal B; Black MM; McGibbon DH
Br J Dermatol; 1997 Feb; 136(2):253-6. PubMed ID: 9068744
[TBL] [Abstract][Full Text] [Related]
14. Expression of selected neuropeptides in pathogenesis of bullous pemphigoid and dermatitis herpetiformis.
Cynkier A; Zebrowska A; Wągrowska-Danilewicz M; Danilewicz M; Erkiert-Polguj A; Stasikowska-Kanicka O; Sysa-Jędrzejowska A; Waszczykowska E
Pol J Pathol; 2012 Mar; 63(1):31-9. PubMed ID: 22535604
[TBL] [Abstract][Full Text] [Related]
15. Mixed form of dermatitis herpetiformis and bullous pemphigoid.
Falk ES; Rekvig OP
Acta Derm Venereol; 1980; 60(3):229-34. PubMed ID: 6158225
[TBL] [Abstract][Full Text] [Related]
16. Expression of selected adhesion molecules in dermatitis herpetiformis and bullous pemphigoid.
Zebrowska A; Waszczykowska E; Wagrowska-Danilewicz M; Danilewicz M; Erkiert-Polguj A; Pawliczak R; Sysa-Jedrzejowska A
Pol J Pathol; 2009; 60(1):26-34. PubMed ID: 19670701
[TBL] [Abstract][Full Text] [Related]
17. The imbalance between metalloproteinases and their tissue inhibitors is involved in the pathogenesis of dermatitis herpetiformis.
Zebrowska A; Narbutt J; Sysa-Jedrzejowska A; Kobos J; Waszczykowska E
Mediators Inflamm; 2005 Dec; 2005(6):373-9. PubMed ID: 16489258
[TBL] [Abstract][Full Text] [Related]
18. Endomysium and antigliadin antibodies in dermatitis herpetiformis and other bullous diseases.
Economidou J; Avgerinou G; Tsiroyianni A; Stavropoulos P; Vareltzidis A; Katsambas A
J Eur Acad Dermatol Venereol; 1998 Sep; 11(2):184-5. PubMed ID: 9784051
[No Abstract] [Full Text] [Related]
19. Evidence for a role of autoantibodies to heat shock protein 60, 70, and 90 in patients with dermatitis herpetiformis.
Kasperkiewicz M; Tukaj S; Gembicki AJ; Silló P; Görög A; Zillikens D; Kárpáti S
Cell Stress Chaperones; 2014 Nov; 19(6):837-43. PubMed ID: 24643797
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous endothelial cell activation in normal skin of patients with dermatitis herpetiformis associated with increased serum levels of IL-8, sE-Selectin, and TNF-alpha.
Hall RP; Takeuchi F; Benbenisty KM; Streilein RD
J Invest Dermatol; 2006 Jun; 126(6):1331-7. PubMed ID: 16575390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
